- Home
- LDI vs EDIT Comparison
LDI vs EDIT Comparison
Compare LDI & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LDI
- EDIT
- Stock Information
- Founded
- LDI 2010
- EDIT 2013
- Country
- LDI United States
- EDIT United States
- Employees
- LDI N/A
- EDIT N/A
- Industry
- LDI Finance: Consumer Services
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LDI Finance
- EDIT Health Care
- Exchange
- LDI Nasdaq
- EDIT Nasdaq
- Market Cap
- LDI 221.2M
- EDIT 263.7M
- IPO Year
- LDI 2021
- EDIT 2016
- Fundamental
- Price
- LDI $1.96
- EDIT $3.03
- Analyst Decision
- LDI Sell
- EDIT Buy
- Analyst Count
- LDI 2
- EDIT 12
- Target Price
- LDI $2.05
- EDIT $5.40
- AVG Volume (30 Days)
- LDI 2.0M
- EDIT 2.5M
- Earning Date
- LDI 08-07-2025
- EDIT 08-12-2025
- Dividend Yield
- LDI N/A
- EDIT N/A
- EPS Growth
- LDI N/A
- EDIT N/A
- EPS
- LDI N/A
- EDIT N/A
- Revenue
- LDI $1,124,074,000.00
- EDIT $38,901,000.00
- Revenue This Year
- LDI $26.92
- EDIT N/A
- Revenue Next Year
- LDI $15.27
- EDIT N/A
- P/E Ratio
- LDI N/A
- EDIT N/A
- Revenue Growth
- LDI 27.06
- EDIT N/A
- 52 Week Low
- LDI $1.01
- EDIT $0.91
- 52 Week High
- LDI $3.23
- EDIT $4.19
- Technical
- Relative Strength Index (RSI)
- LDI 61.12
- EDIT 59.27
- Support Level
- LDI $1.77
- EDIT $2.07
- Resistance Level
- LDI $2.02
- EDIT $3.17
- Average True Range (ATR)
- LDI 0.18
- EDIT 0.24
- MACD
- LDI 0.01
- EDIT 0.02
- Stochastic Oscillator
- LDI 79.84
- EDIT 87.27
About LDI loanDepot Inc.
loanDepot Inc provides nonbank consumer lending solutions for individuals in the United States. It offers personal, residential home, home refinancing, mortgage and home equity loans. It also provides online mortgage loans for refinancing and home purchases. It serves customers through distribution channels, including consumer direct centres, retail branches, wholesale centres, and consumer finance and servicing centres in the United States. It competes with commercial banks and financial institutions.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.